Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants

Phase 4

Completed

• Conditions: Intermittent Claudicants
• Interventions: Drug: Ramipril

• Registration Number: NCT01037530
• Lead Sponsor: Daniel Carradice

Brief Summary

The investigators are conducting a randomised controlled trial to investigate the clinical and cost effectiveness of Ramipril which is an anti-hypertensive medication in patients with intermittent claudication. The investigators aim to recruit 78 participants in total. The investigators will randomise the 78 participants into two groups: Ramipril group with 39 participants and Placebo group with 39 participants. The investigators will measure Ramipril's effect on walking by doing a simple treadmill test and measuring the maximum walking distance the participant can walk. The investigators also want to examine Ramipril's effect on arterial function, cardiovascular prognosis, quality of life and cost effectiveness.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-12-22
• Study First Submitted QC: 2009-12-22
• Study First Posted: 2009-12-23
• Study Start: 2010-12
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-18
• Last Update Posted: 2014-12-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Patients with unilateral or bilateral intermittent leg claudication which was stable for the last 6 months.
• Patients with ABPI < 0.9 at rest at least in one leg.
• BP ≤ 160/90 and a stable medication regimen for the last 6 months.
• Able to give informed consent
• Able to comply with study protocol

Exclusion Criteria

• Documented bilateral renal artery stenosis

• Unlikely to be compliant with medication or follow up as determined by the recruiting institution.

• Pregnancy

• Patients with critical limb ischemia (This includes patients with ischaemic rest pain and ulceration > 2 weeks and/or a resting ankle pressure < 50mmHg- Grades II and III according to Rutherford et al 1997.[56].

• Patients who had a recent (less than 3 months) angioplasty or bypass surgery

• Patients who are unable to perform a treadmill test due to a limiting heart, respiratory or arthritic disease

• History of angioneurotic oedema

• Currently taking ACE inhibitor or Angiotensin receptor blocker

• Contraindication to ACE inhibitor

• History of ACE inhibitor intolerance

• A creatinine rise of > 30% from baseline and/or Potassium > 5.9 mmol/l

• Unwillingness to participate.

• Level 1 evidence for ACE inhibitor treatment, including:

• Documented heart failure, left ventricular dysfunction or ejection fraction <35% on previous echocardiography

  • Uncontrolled hypertension, BP > 160mmHg systolic or 100mmHg diastolic on 3 separate readings measured after 10 minutes rest on 2 separate occasions
  • Recent (< 3months) myocardial infarction or stroke
  • Chronic renal impairment (serum creatinine > 250 micromol/l)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ramipril	Ramipril	-

Primary Outcome Measures

Name	Time	Method
The primary outcome measure for this trial is the Maximum Walking Distance (MWD). Treadmill exercise test will be used to estimate the maximum distance the participant can walk at a speed of 2.5 km/h with a 10 degree incline.	0,2,6,24 weeks

Secondary Outcome Measures

Name	Time	Method
Other clinical indicators of lower limb ischaemia: a) Patient Reported Walking Distance (PRWD) b) Treadmill Intermittent Claudication Distance (ICD) c) Ankle Brachial Pressure Index at rest (ABPI- r) and following treadmill testing (ABPI - t)	0,2,6,24 weeks
Cardiovascular prognosis using: a) Framingham, PROCAM, QRISK and Manchester charts scoring systems b) B-type Natriuretic Peptide (BNP) and N- terminal prohormone BNP (NT-proBNP) and a Lipid profile ( LDL, HDL, Total Cholesterol, Triglycerides)	0,2,6,24 weeks
Quality of life: a) Generic - measured using the SF36, SF8 and EuroQol (EQ5D) instruments b) Disease specific - measured using the VascuQol	0,2,6,24 weeks
Markers of endothelial function and ischaemia reperfusion a) IL6 b) soluble Intercellular Adhesion Molecule-1 (sICAM -1) c) sE selectin d) Urine Albumin Creatinine Ratio ( UACR)	0,2,6,24 weeks
Arterial effects: a) Arterial stiffness by measuring the Pulse Wave Velocity and assessing the effects on the extracellular matrix by measuring Metalloproteinases (MMPs) and Tissue Inhibitor Metalloproteinases (TIMPs). b) Flow mediated vasodilatation	0,2,6,24 weeks
Health economics (cost effectiveness / utility)	24 weeks

Trial Locations

Locations (1)

Hull and East Yorkshire Hospitals; 🇬🇧 Hull, Yorkshire, United Kingdom